H. Dulude

发表

Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study

J. Yale, M. Egeth, H. Dulude, 2017, Diabetes technology & therapeutics.

Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding.

R. Béliveau, B. Annabi, S. Rabbani, 2006, Biochemical and biophysical research communications.

Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.

L. Tye, P. Goss, A. Stewart, 1999, Leukemia & lymphoma.

Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.

E. Bruera, J. Hanson, S. Ernst, 1998, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

E. Seaquist, S. Weisnagel, R. Rabasa-Lhoret, 2018, Diabetes, obesity & metabolism.

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

S. Gertler, G. Goss, E. Tomiak, 1996, Lung cancer.

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

L. Seymour, H. Hirte, D. Lebwohl, 2002, Gynecologic oncology.

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

E. Warner, J. Dancey, E. Franssen, 1998, British Journal of Cancer.

Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling

R. Béliveau, B. Annabi, S. Rabbani, 2006, Anti-cancer drugs.

A phase I/II study of paclitaxel (TAXOL) and concurrent radiotherapy in advanced nonsmall cell lung cancer.

E. Eisenhauer, K. Gelmon, P. Kirkbride, 1997, International journal of radiation oncology, biology, physics.

Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.

A. Oza, M. Moore, E. Franssen, 1998, American journal of clinical oncology.

Synthesis, anti-HIV and anti-Proliferative Activity of New Urea and Nitrosourea Derivatives of Amino Acids

G. Gallant, H. Dulude, R. Salvador, 1991 .

Synthesis and in vitro anti-HIV and antitumor activity of new 2-chloroethyl thiocarbamates

G. Gallant, H. Dulude, R. Salvador, 1995 .

Synthesis, chemical half-life and decomposition of new N3-(substituted) derivatives of CCNU

G. Gallant, H. Dulude, R. Salvador, 1994 .

Synthesis and anti-HIV activity of new urea and nitrosourea derivatives of diamino acids.

G. Gallant, H. Dulude, R. Salvador, 1995, Bioorganic & medicinal chemistry.

In vitro carboplatin-mesna interaction in aqueous solution, human plasma and urine.

F. Shirazi, D. Stewart, M. Obrocea, 1998, Oncology reports.

A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor Metastasis

R. Béliveau, B. Annabi, S. Rabbani, 2005, Clinical & Experimental Metastasis.

Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer.

C. Earle, S. Dahrouge, S. Gertler, 1997, Lung cancer.

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer.

S. Glück, P. Cano, T. Koski, 1998, European journal of cancer.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes

R. Beck, M. Rickels, R. Wadwa, 2016, Diabetes Care.

A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.

K. Gelmon, D. Ayers, A. Tolcher, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.

J. R. Reeves, J. Trachtenberg, S. Narod, 2006, The Journal of urology.

Prognostic Value of Prostate Secretory Protein of 94 Amino Acids and its Binding Protein after Radical Prostatectomy

J. R. Reeves, D. Ramnani, C. Panchal, 2006, Clinical Cancer Research.

Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial

E. Rampakakis, É. Sicard, H. Dulude, 2017, Diabetes, obesity & metabolism.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study

R. Beck, M. Rickels, R. Wadwa, 2015, Diabetes Care.

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.

R. Cowan, R. Hawkins, A. Armstrong, 2005, Clinical prostate cancer.

A phase II trial of mitomycin, ifosfamide and cisplatin in recurrent carcinoma of the cervix.

B. Leyland-Jones, L. Souhami, M. Trudeau, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

In vitro cytotoxicity and differential cellular sensitivity of new N-methyl and N-propargyl urea and nitrosourea derivatives of diamino acids against sixty human NCI tumor cell lines.

G. Gallant, H. Dulude, R. Salvador, 1993, Anticancer research.